手机网
关键词
首页>>正文

万众瞩目!2021 AHA年会哪些内容值得关注?
[2021/11/19 10:44:44]
 全文(共1页)
  2021美国心脏协会(AHA)科学年会将在美国东部时间11月13日~11月15日在线上召开。大会以演讲、专题会、口头报告等形式展示了心脏病领域的研究进展。本次AHA大会有哪些热点内容值得重点关注呢?
 
 
  不容错过的大事件
 
  11月13日9:30 AM
 
  肿瘤心脏病学:从科学到患者
 
  11月13日11:00 AM
 
  ACC/AHA瓣膜性心脏病指南:你需要知道什么以及接下来会发生什么
 
  11月13日3:00 PM
 
  2021年的心房颤动:为新方向做好准备
 
  2021年改善心血管健康的饮食指南
 
  11月14日3:30 PM
 
  新的心力衰竭指南应在哪些方面做出改变?
 
  杰出科学家讲座
 
  11月15日9:30 AM
 
  胸痛指南
 
  更多精彩内容查看下图
 
 
 
  11月13日----Late-Breaking Science
 
  LBS.01--心胸外科的瓣膜、静脉和新观点
 
  Aortic Valve Replacement Versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The Avatar Trial (AVATAR)
 
  主动脉瓣置换术与无症状严重主动脉瓣狭窄的观察等待:AVATAR试验
 
  Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery
 
  评估二尖瓣手术合并三尖瓣修复的获益
 
  A Randomized Study of Early Versus Standard Coronary Artery Bypass Surgery Among Patients Presenting With Acute Coronary Syndromes Treated With Ticagrelor (RAPID CABG)
 
  RAPID CABG:接受替格瑞洛治疗的急性冠状动脉综合征患者早期与标准冠状动脉搭桥手术的随机研究
 
  Efficacy and Safety of an External Support Device for Saphenous Vein Coronary Bypass Grafts: The VEST Trial (VEST)
 
  一种大隐静脉冠状动脉旁路移植术外部支撑装置的有效性和安全性:VEST试验
 
  LBS.02--高血压:本地、全球和大流行的影响
 
  A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network
 
  通过多元化的医疗保健网络,针对10,000名患者的远程高血压和血脂项目
 
  Disruption in Blood Pressure Control With the Covid-19 Pandemic: A Study of 24 U.S. Health Systems in the PCORnet Blood Pressure Control Laboratory (BP Track)
 
  BP Track:Covid-19大流行对血压控制的破坏:PCORnet血压控制实验室对24 个美国卫生系统的研究统的研究
 
  A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project (CRHCP)
 
  乡村医生主导的干预血压控制集群随机试验:中国农村高血压控制项目(CRHCP)
 
  11月14日----Late-Breaking Science
 
  LBS.03--房性心律失常的预防干预
 
  The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) Trial (CRAVE)
 
  咖啡和实时心房和心室异试验( CRAVE )
 
  Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of the GIRAF Trial. (GIRAF)
 
  达比加群与华法林对非瓣膜性房颤认知结果的影响:GIRAF试验结果。
 
  Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS)
 
  左后心包切开术减少心脏手术后房颤( PALACS )
 
  Outcomes of Adjunctive Left Atrial Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial (AMAZE)
 
  与单独肺静脉窦隔离相比,使用LARIAT辅助左心耳结扎术的结果:AMAZE试验
 
  LBS.04--信息超载?努力通过数字健康和自动化数据改善医疗服务
 
  Risk Evaluation and its Impact on Clinical Decision-Making and Outcomes in Heart Failure: The REVeAL-HF Trial (REVeAL-HF)
 
  心力衰竭风险评估及其对临床决策和结果的影响:REVeAL-HF试验
 
  Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
 
  使用可穿戴设备检测大量人群的心房颤动:Fitbit心脏研究
 
  Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)
 
  测试心房颤动的个体化触发因素:一项随机对照试验( I-STOP-AFib )
 
  LBS.05--以治疗为基础:心力衰竭治疗的进展
 
  Heart Failure With a Preserved Ejection Fraction ≥50% - Results From the EMPEROR-Preserved Clinical Trial (EMPEROR-Preserved)
 
  射血分数≥50%的心力衰竭-来自EMPEROR-Preserved临床试验的结果
 
  The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial (CHIEF-HF)
 
  卡格列净对心力衰竭患者健康状况、生活质量和功能状态的影响 (CHIEF-HF) 临床试验
 
  Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial (EMPULSE)
 
  恩格列净在心力衰竭住院患者的疗效和安全性:来自EMPULSE试验的主要结果
 
  Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients With Reduced Ejection Fraction (DREAM-HF)
 
  射血分数降低的高危慢性心力衰竭患者经心内膜靶向输送间充质前体细胞的随机试验( DREAM-HF )
 
  11月15日----Late-Breaking Science
 
  LBS.06--鱼油、可可和胆固醇:预防心血管疾病的食谱?
 
  Icosapent Ethyl Versus Placebo in Outpatients With Covid-19: The Main Results of PREPARE-IT 2 (PREPARE-IT 2)
 
  在Covid-19门诊患者中使用Icosapent Ethyl与安慰剂:PREPARE-IT 2的主要结果
 
  The Clinical Safety, Pharmacokinetics and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor
 
  MK-0616(一种口服PCSK9抑制剂)的临床安全性、药代动力学和降低低密度脂蛋白胆固醇的疗效
 
  LBS.07--心血管疾病新药及新药适应证
 
  Effects of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial (ASCEND)
 
  在ASCEND试验中阿司匹林对痴呆和认知障碍的影响
 
  P2y12 Inhibitors in Noncritically Ill Hospitalized Patients With Covid-19 (ACTIV-4A)
 
  ACTIV-4A:P2y12抑制剂在Covid-19非危重住院患者的应用
 
  Effect Of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients With Uncontrolled Hemorrhage or Requiring Urgent Surgery in the REVERSE-IT (REVERSE-IT)
 
  REVERSE-IT :Bentracimab对替格瑞洛患者不可控出血或需要紧急手术的血小板抑制和止血的影响
 
  Milvexian for Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study (AXIOMATIC-TKR)
 
  Milvexian用于预防择期膝关节置换术后静脉血栓栓塞:AXIOMATIC-TKR研究
 
  以上是2021 AHA的热点内容,后续《国际循环》将就这些热点内容进行深入的报道,敬请关注!




更多热点
更多   心血管   相关搜索
声明:登陆《国际循环》手机网不收业务信息费,只产生运营商收取的上网流量费。
返回顶端| About Us | 客服中心 |收藏本站
WapURL手机网址(wap.icirculation.com)